With the public availability of ChatGPT 3.5 in fall 2022 at the latest, artificial intelligence in the sense of large language models (LLMs) is on everyone’s lips. However, it is often forgotten that this is only the provisional end point of decades of development of artificial intelligence, which, despite its great potential, still has many limitations. The question for practising doctors is how this technology can be used sensibly in everyday clinical practice – and how it should not be used.
Autoren
- Dr. med. Lukas Dürst
- Dr. med. Marc Oertle
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- Adherence in severe or poorly controlled asthma
Digital monitoring with potential for greater treatment adherence
- GLA:D® program for back pain patients